PROCRIT 40,000 IU QW + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral Neuropathy, Chemotherapy-induced
Conditions
Peripheral Neuropathy, Chemotherapy-induced
Trial Timeline
Jun 1, 2006 → Aug 1, 2008
NCT ID
NCT00267007About PROCRIT 40,000 IU QW + Placebo
PROCRIT 40,000 IU QW + Placebo is a phase 2 stage product being developed by Johnson & Johnson for Peripheral Neuropathy, Chemotherapy-induced. The current trial status is terminated. This product is registered under clinical trial identifier NCT00267007. Target conditions include Peripheral Neuropathy, Chemotherapy-induced.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00267007 | Phase 2 | Terminated |
Competing Products
20 competing products in Peripheral Neuropathy, Chemotherapy-induced